Gummy and Softgel Supplement Manufacturing: Content Uniformity, Water Activity and Matrix-Specific Controls

Gummies are produced by deposition of a hot liquid slurry into starch or silicone moulds. Active uniformity depends on slurry homogeneity at the depositor head, depositor accuracy across moulds, settling and segregation in the slurry tank, and the active's solubility or suspendability in the hot matrix. Heat-sensitive actives may degrade during the prolonged residence at deposition temperature (typically 70-95 °C for gelatin gummies, lower for pectin); poorly soluble actives stratify in the tank, producing systematic mould-to-mould drift across a batch. Effective controls: validated depositor weight variation studies, in-process content uniformity sampling at multiple time points across the deposition run (start, mid, late), active-specific suspendability or pre-blend strategy, and a tightened release specification on content uniformity that catches drift before the consumer does. 21 CFR 111 requires content uniformity testing as part of finished-product release; under-specifying the sampling plan is a recurring 483 source.

Gummies sit at water activity (aw) 0.5-0.7, well above the threshold where microbial growth becomes possible. Microbiological control depends on (1) the soluble solids and pH of the matrix (sugar-saturated, pH 3.5-4.5 for fruit-flavoured products inhibits most pathogens but does not eliminate spoilage organisms), (2) the moisture migration profile during shelf life (gummies dry out and become tough, or absorb moisture and become sticky depending on packaging humidity), (3) the choice between gelatin (animal-derived, melts in the mouth, lower aw at equivalent texture) and pectin (plant-derived, vegan, higher aw, sets via calcium and sugar). Microbiological specifications per USP <2021>, USP <2022> and house-specific challenge testing — Total Aerobic Microbial Count, Total Combined Yeasts and Moulds, E. coli, Salmonella, Staphylococcus aureus — must be set, enforced at release and trended across stability. Heat-sensitive probiotic and enzyme actives are typically incompatible with the gummy matrix without strain selection (spore-forming Bacillus strains) or specialised encapsulation.

The gummy matrix is reactive: heat, residual moisture, reducing sugars (Maillard reactions with amino acids), pH and oxygen all drive active degradation. Common active loss patterns: vitamin C (oxidative loss, accelerated by metal ion catalysis and moisture), B vitamins (heat-sensitive, particularly thiamine and folate), vitamin D (oxidation and light), melatonin (relatively stable but with crystallinity issues), botanicals (matrix interactions, marker compound shift). Overage is set from stability data, not from compendial guesses — typical overages range from 10% for stable actives to 50%+ for fragile actives across a 24-month shelf life. Overage strategy interacts with label upper-limit compliance: an overage that delivers label at month 24 may exceed the upper specification at month 0, particularly for actives with regulatory upper limits (vitamin A, vitamin D in some jurisdictions). Stability data over the full shelf life, not just accelerated 3-month data, is required to set overage defensibly.

Softgels are produced by rotary die encapsulation: two ribbons of warm gelatin (or non-animal alternative such as carrageenan-modified starch) are pressed between counter-rotating dies as the liquid or suspension fill is injected; the dies cut, seal and eject the capsules. Critical controls: (1) fill homogeneity — for suspensions, active particle size, settling and shear-thinning behaviour determine dose uniformity capsule-to-capsule; (2) shell composition — gelatin grade (Bloom strength, viscosity), plasticiser (glycerin, sorbitol) ratio, water content and any added opacifiers (titanium dioxide, with EFSA having banned its food use, requiring reformulation for EU-marketed product); (3) seal integrity — bubble or split-seam capsules leak fill, fail uniformity and grow microbiologically; (4) drying — wet capsules are dried in tumble dryers and trays to a target shell moisture (typically 8-12% for gelatin), with under-drying causing tackiness and over-drying causing brittleness; (5) crosslinking — gelatin can crosslink during shelf life (particularly with reducing-sugar or aldehyde-bearing fills), producing a 'pellicle' that retards dissolution. Two-stage dissolution testing (with and without enzymes) is the standard surveillance method.

Both gummies and softgels carry a specific failure mode the consumer never sees but a regulator or third-party tester does: the active is present in the product (assay passes) but does not release in vivo (dissolution fails). For gummies, this occurs when an active binds to the matrix or precipitates during gel setting. For softgels, gelatin crosslinking is the dominant cause. Dissolution testing per USP <711> with media and apparatus appropriate to the dosage form, run at release and across stability, catches the issue. Bioavailability comparisons (in vitro dissolution as surrogate, in vivo PK as definitive) become particularly important when reformulating from one dosage form to another or from one matrix to another — a label claim of equivalence to a tablet form requires evidence, not assumption. Independent third-party testing programmes (ConsumerLab, NSF spot-checks, retailer surveillance) routinely identify dissolution failures in gummies and softgels that passed manufacturer assay testing.